×
Inozyme Pharma Net Cash Flow 2020-2025 | INZY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Inozyme Pharma net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
Inozyme Pharma Net Cash Flow 2020-2025 | INZY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Inozyme Pharma net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$228.5B
Amgen (AMGN)
$165.9B
Gilead Sciences (GILD)
$140.8B
Vertex Pharmaceuticals (VRTX)
$121.3B
Bristol Myers Squibb (BMY)
$99.6B
CSL (CSLLY)
$86.2B
GSK (GSK)
$78.3B
Regeneron Pharmaceuticals (REGN)
$61B
Alnylam Pharmaceuticals (ALNY)
$42.8B
Argenex SE (ARGX)
$36.2B
BioNTech SE (BNTX)
$27.5B
Royalty Pharma (RPRX)
$20.6B
Insmed (INSM)
$19.6B
Biogen (BIIB)
$19.4B
Illumina (ILMN)
$17B
Genmab (GMAB)
$15.2B
Genmab (GNMSF)
$14.9B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.2B
Exelixis (EXEL)
$12.2B
BioMarin Pharmaceutical (BMRN)
$11.5B
QIAGEN (QGEN)
$11.4B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.3B
Exact Sciences (EXAS)
$9.2B
Bio-Techne Corp (TECH)
$9.2B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.3B
Legend Biotech (LEGN)
$8.1B
Roivant Sciences (ROIV)
$7.7B